Dr. Kerry B. Goralski, PhD
Professor, College of Pharmacy, and Cross Appointment to Department of Pharmacology
Development of new anti-cancer drugs for drug resistant metastatic breast cancer, obesity and endocrine function of fat tissue, preclinical and clinical pharmacology and pharmacokinetics, drug transport and metabolism
Membrane drug pumps and multidrug resistant metastatic breast cancer
Multidrug resistance remains a serious problem in the effective treatment of metastatic breast cancer. One way that breast cancer cells develop resistance is by increasing their number of cell membrane drug pumps (e.g. P-glycoprotein) that remove helpful chemotherapy from the inside of cancer cells. Our research has shown that a class of bacterial-derived natural product molecules called jadomycins escape P-glycoprotein function, allowing them to kill cultured breast cancer cells that are resistant to other chemotherapy drugs. Our current pharmacological research focuses on determining how jadomycins kill breast cancer cells, if jadomycins kill breast cancer cells without harming noncancerous cells and if jadomycins prevent breast cancer growth and metastasis in zebrafish and mouse experimental models. Through this research, we can better understand how jadomycins could be used to treat patients in a clinical setting, and also learn more about metastatic breast cancer as a disease.